JP7607895B2 - Ｉ型およびｉｉｉ型インターフェロン融合分子ならびにこれらの使用のための方法 - Google Patents

Ｉ型およびｉｉｉ型インターフェロン融合分子ならびにこれらの使用のための方法 Download PDF

Info

Publication number
JP7607895B2
JP7607895B2 JP2019559715A JP2019559715A JP7607895B2 JP 7607895 B2 JP7607895 B2 JP 7607895B2 JP 2019559715 A JP2019559715 A JP 2019559715A JP 2019559715 A JP2019559715 A JP 2019559715A JP 7607895 B2 JP7607895 B2 JP 7607895B2
Authority
JP
Japan
Prior art keywords
ifn
type
fusion molecule
interferon
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019559715A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020518588A (ja
JP2020518588A5 (enExample
Inventor
コテンコ，セルゲィ，ブイ．
ダービン，ジョアン
ダブラ，バイラルクマール，ラメシュクマール
Original Assignee
ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー filed Critical ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー
Publication of JP2020518588A publication Critical patent/JP2020518588A/ja
Publication of JP2020518588A5 publication Critical patent/JP2020518588A5/ja
Application granted granted Critical
Publication of JP7607895B2 publication Critical patent/JP7607895B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/18—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N<, e.g. carboxylic acid amides or imides; Thio analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Plant Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2019559715A 2017-05-01 2018-05-01 Ｉ型およびｉｉｉ型インターフェロン融合分子ならびにこれらの使用のための方法 Active JP7607895B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762492373P 2017-05-01 2017-05-01
US62/492,373 2017-05-01
PCT/US2018/030370 WO2018204312A1 (en) 2017-05-01 2018-05-01 Type i and type iii interferon fusion molecules and methods for use thereof

Publications (3)

Publication Number Publication Date
JP2020518588A JP2020518588A (ja) 2020-06-25
JP2020518588A5 JP2020518588A5 (enExample) 2021-06-10
JP7607895B2 true JP7607895B2 (ja) 2025-01-06

Family

ID=64016582

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019559715A Active JP7607895B2 (ja) 2017-05-01 2018-05-01 Ｉ型およびｉｉｉ型インターフェロン融合分子ならびにこれらの使用のための方法

Country Status (6)

Country Link
US (1) US11292823B2 (enExample)
EP (1) EP3618618A4 (enExample)
JP (1) JP7607895B2 (enExample)
AU (1) AU2018261750A1 (enExample)
CA (1) CA3061864A1 (enExample)
WO (1) WO2018204312A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024192373A1 (en) * 2023-03-16 2024-09-19 A-Alpha Bio Interferon alpha-2 variants
US12281147B2 (en) 2023-08-14 2025-04-22 A-Alpha Bio, Inc. Interleukin 21 variants

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008508310A (ja) 2004-07-29 2008-03-21 ザイモジェネティクス， インコーポレイテッド がんおよび自己免疫障害を治療するためのｉｌ−２８およびｉｌ−２９の使用法
JP2011045375A (ja) 2003-07-21 2011-03-10 Transgene Sa 新規多機能性サイトカイン

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939286A (en) * 1995-05-10 1999-08-17 University Of Florida Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them
US7232563B2 (en) 2001-08-12 2007-06-19 Pepgen Corporation Hybrid interferon/interferon tau proteins, compositions and methods of use
CN101918440B (zh) * 2007-09-20 2015-04-22 联邦科学技术研究组织 禽类细胞因子及编码其的遗传序列的应用
CN102212539B (zh) * 2011-04-08 2012-10-24 山东省农业科学院畜牧兽医研究所 高效表达的串联猪α、γ干扰素基因及其表达蛋白的用途
LT6164B (lt) 2013-10-15 2015-06-25 Uab Biotechnologinės Farmacijos Centras "Biotechpharma" Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas
CN106674354B (zh) * 2017-02-14 2020-10-16 华南农业大学 一种鸡干扰素IFN-λ与IFN-α的融合蛋白
AU2018307752A1 (en) * 2017-07-24 2020-03-12 Rutgers, The State University Of New Jersey Phosphatidylserine targeting fusion molecules and methods for their use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011045375A (ja) 2003-07-21 2011-03-10 Transgene Sa 新規多機能性サイトカイン
JP2008508310A (ja) 2004-07-29 2008-03-21 ザイモジェネティクス， インコーポレイテッド がんおよび自己免疫障害を治療するためのｉｌ−２８およびｉｌ−２９の使用法

Also Published As

Publication number Publication date
US11292823B2 (en) 2022-04-05
AU2018261750A1 (en) 2019-11-14
JP2020518588A (ja) 2020-06-25
EP3618618A1 (en) 2020-03-11
US20200071375A1 (en) 2020-03-05
CA3061864A1 (en) 2018-11-08
EP3618618A4 (en) 2020-03-25
WO2018204312A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
ES2752248T5 (es) Heterodímero proteínico y uso del mismo
EP2519250B1 (en) Interferon analogs
US8187584B2 (en) Human tumor necrosis factor-α mutants
Chevaliez et al. Interferon-based therapy of hepatitis C
CA2809900C (en) Use of interleukin-22 in treating viral hepatitis
JP2008545409A (ja) インターフェロン−ＩｇＧ融合体
JP2025072475A (ja) 可溶性インターフェロン受容体およびその使用
TW200900504A (en) Recombinant human interferon-like proteins
JP7221545B2 (ja) ホスファチジルセリン標的化融合分子およびそれらの使用方法
PL197568B1 (pl) Kompleks zawierający IFN typu I oraz podjednostkę IFNAR, jego zastosowanie, cząsteczka DNA i wektor ją zawierający, komórka gospodarza transformowana wektorem, kompozycja farmaceutyczna, lek, zastosowanie IFNAR, zastosowanie IFN typu I i podjednostki IFNAR, sposób wytwarzania białka fuzyjnego oraz sposób przedłużania okresu trwałości IFN
JP7607895B2 (ja) Ｉ型およびｉｉｉ型インターフェロン融合分子ならびにこれらの使用のための方法
CA2843495A1 (en) Hcv immunotherapy
JP2022545265A (ja) 筋萎縮を治療するためのペプチド
Antonelli Biological basis for a proper clinical application of alpha interferons.
KR20080037656A (ko) 저독성의 장시간 순환하는 사람 인터페론-알파 유사체 및인터페론 타우의 키메라
van Dijk Delivery of biologicals: Sustained release of cell-specific proteins in fibrosis
CN116685598A (zh) 干扰素taufc-融合蛋白和治疗方法冠状病毒感染
NZ620689B2 (en) Hcv immunotherapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210426

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220603

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230104

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230104

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230113

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230221

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230222

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230407

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240926

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241211

R150 Certificate of patent or registration of utility model

Ref document number: 7607895

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150